News Hub | News Direct

All Industries


Article thumbnail News Release

Peru Officially Inaugurates Pavilion at Expo 2025 Osaka-Kansai

Promperu

Peru officially inaugurated its national pavilion at Expo 2025 Osaka-Kansai, marking a significant milestone in its participation in one of the world’s most prominent cultural and economic events. The opening ceremony was led by Peru’s Minister of Foreign Trade and Tourism, Desilú León Chempén, alongside the Ambassador of Peru to Japan, Roberto Seminario, and Commissioner General of the Peru Pavilion, Daniel Cavero. Held under the theme “Infinite Possibilities,” the Peru Pavilion offers a dynamic platform to project the country’s rich cultural, historical, and natural heritage to the world. The initiative, led by PROMPERÚ, integrates tradition, innovation, and sustainability, promoting an image of Peru as an opportunity-rich, future-oriented nation. Minister León Chempén emphasized the significance of Peru’s participation: “Expo 2025 Osaka, Kansai is one of the most important global events for cultural, economic, and diplomatic exchange. With over 28 million visitors expected, it presents an unprecedented opportunity to showcase Peru’s richness, diversity, and potential to the world. Our participation, aligned with the theme ‘Infinite Possibilities,’ allows us to promote an image of Peru as an innovative, sustainable, and opportunity-rich country.” Guests explored immersive exhibitions such as “The Treasures of the Lord of Sipán” and “Peru and Japan”, celebrating the historical and cultural ties between both nations. Live gastronomic demonstrations delighted attendees with tastings of Peru’s iconic dishes, including ceviche, and the world-famous cocktail pisco sour, made from the country’s national spirit, pisco. As part of the inaugural event, the Embassy of Peru in Japan unveiled Pukara-chan, the official mascot of the pavilion. Inspired by the traditional toro de Pucará —a symbol of prosperity and protection—Pukara-chan was specially created to commemorate 150 years of diplomatic relations between Peru and Japan. The character will serve as a cultural ambassador throughout the duration of the Expo. The Peru Pavilion promises an engaging experience, inviting visitors to discover the country’s unique blend of ancient traditions, natural wonders, world-renowned cuisine, and modern innovation. With a vision toward a sustainable and interconnected future, the pavilion reflects Peru’s unwavering belief in a world of infinite possibilities. Find out more about Peru's participation in Expo 2025 Osaka Kansai on social media: https://www.instagram.com/peru.expo2025/ https://x.com/peruatexpo https://www.tiktok.com/@peruatexpo https://www.youtube.com/@Peruatexpo2025 Peru Export and Tourism Promotion Board (PROMPERÚ). We are the government agency in charge of the development and implementation of global strategies to position Peru via the promotion of its image, touristic destinations, added value exports and investments. Contact Details José Carlos Collazos jcollazos@promperu.gob.pe Company Website http://www.promperu.gob.pe

April 14, 2025 09:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

The PR Net Future Focus 2025 Brings Together Industry Leaders for a Day of Insights and Innovation

The PR Net

On April 4th, The PR Net hosted its third annual Future Focus Conference, a full-day summit that brought together global leaders across media, marketing, technology, and communications to explore the bold ideas, technologies, and strategies shaping the future of the industry. With over 250 senior executives in attendance and ten future-forward panel discussions, the event offered a platform for critical dialogue, practical insights, and invaluable networking. Digital recordings of the 2025 Future Focus Conference are now available for pre-order. Revisit every panel, speaker insight, and key moment at your convenience. [www.theprnet.com/futurefocustickets] The day began with How to Thrive During the Great Media Disruption, which addressed the challenge of building trust and relevance in today’s fragmented landscape. Dan Simon, Founder of Qwoted, emphasized the shift toward community-driven media: “Group chat is really interesting. We can’t fully measure it yet - it’s kind of the dark social of the medium. But once we can, it’ll be clear that people trust people more than they trust brands.” Helen Tobin, Head of Communications at Substack, echoed this theme, adding, “What’s valuable now is having an authentic voice. People subscribe because they feel a genuine connection and want to get someone’s perspective.” Andy Pray, Founder of Praytell, pointed to the role of AI in enhancing storytelling: “AI allows smart people to be smarter. It helps us skip the grunt work and focus on the story.” The second panel, Social Impact Strategies: The Case for Brands Doing Good, focused on how businesses can build brand equity through purpose. “Doing good is good for business,” said Crystal Carroll, Head of PR at Ulta Beauty. “As a consumer, you want brands that align with your values.” Anna Doré of Rothy’s stressed the need for consistency: “It’s not about short-term sales - it’s about long-term value.” Rachel Henderson Eliff of Fenton added, “When you truly listen to your communities and respond to their needs, it leads to better outcomes - better profits and stronger, more meaningful brands.” In Owning the Narrative: Staying in Control in the Age of AI, panelists explored how communicators can maintain brand voice while leveraging technology. “Using AI can be like onboarding a new hire,” said Samyutha Reddy, Strategic Advisor and former Head of Marketing at Jasper AI. “It’s smart, but without the right context, training, and time, it won’t be effective.” Parker Olson, Co-Founder of PodPitch, encouraged experimentation: “Go and play with tools. Block your calendar for an hour every Friday to explore. Just play, play, play with AI.” Paul Miser, EVP at 5WPR, framed AI as a strategic asset: “It helps map the ecosystem, define the right narrative, clarify the CEO’s role in it, and build a roadmap for content and thought leadership.” Erica Vlahinos of OpenAI emphasized the human factor: “We’re going to see the currency of what only humans can do increase. People will spend more time connecting and creating—rather than just doing tasks.” Maximizing Affiliate Marketing in a Changing Media Landscape tackled performance, measurement, and relevance. “Reddit is in the middle or lower funnel—we might hate it as industry people, but it’s the most authentic conversation about your brand that people trust,” said moderator Nik Sharma of Sharma Brands. Courtney Vanpraag of impact.com explained, “With full visibility into every touchpoint, you can see the true impact of your press.” Paddy Cleary of Paul Street urged brands to learn from their audience: “Promote honest reviews from your audience. These channels require very specific approaches.” Teresa Grammatke of eAccountable concluded, “Be where your audience is - whether that’s Reddit, Substack, or anywhere else.” The panel What’s Next in Influencer Marketing? examined the evolution from celebrity endorsements to community trust. “A brand’s success isn’t just about reaching audiences—it’s about earning their trust through creators and the communities they build,” said Jo Cronk of Whalar. Mary Ogushwitz of Magrino emphasized strategy over scale: “Just having a list of top influencers isn’t strategic and won’t meet your goals.” Sara Feder of WeArisma reinforced the power of smaller voices: “Often, it’s the cool kid in Austin or Atlanta who’s actually making brands relevant.” Patrick Janelle of Untitled Secret added, “With influencers, you either don’t know them—or you’re their biggest fan. That level of affinity is incredibly powerful.” The Power of Brand Partnerships explored how collaborations can become long-term brand builders. “Our biggest fear is coming into the conversation too late. If there isn’t a story to tell, you can’t just PR it,” said Sara Joseph Noyes of BerlinRosen. Eléonore Dethier of Sotheby’s explained, “Every collaboration must tell an authentic story. Less is more - too many partnerships dilute the brand.” Danielle Bias of MOCA noted, “There’s still space for magic to happen… and the ROI is incredible because you can’t orchestrate it.” Moderator Noria Morales distilled the key takeaway: “Partnerships always take longer than you think you need.” AI & The Creator Economy: Redefining Influence and Creativity unpacked how AI is shaping the next wave of content creators. “74% of people are more likely to trust someone like them than an institution,” said moderator Tara Hagan of Edelman. Valerie Chapman of INFRM described the next phase: “We’re shifting from the creator economy to the curator economy. Niche communities will emerge - and brands will have to find them.” Edelman’s Alexia Adana added, “We need transparency - not just from big tech companies, but also from brands.” Melissa Grevstad of Dove grounded the discussion in brand purpose: “Our north star is real beauty. Technology will come and go, but our compass remains.” Seeing the Brand Everywhere: Activating Brand Love at Scale centered on distribution and omnichannel relevance. “Distribution will become increasingly important,” said moderator James Nord of Fohr. “Influencers help you reach the nooks and crannies of the internet.” Marriott’s Stephanie Goldstein explained the shift in value: “The traditional model doesn’t score well when you factor in cost to produce and where attention is focused.” Meredith McLuckie of DICK’S Sporting Goods added, “Influencer content outperforms brand content - and costs a fraction of traditional media.” In The Future of Travel & Hospitality Marketing, panelists emphasized experience and storytelling. “It’s all about that 360-degree approach,” said David Zapata of Zapwater Communications. Jamari A. Douglas of Bermuda Tourism Authority noted, “People love personalization - but we also need to be honest about how we use their data.” Sarah Evans of J/PR added, “Luxury is different for everyone - today it’s not about what’s hot, but what stories we have to tell.” The day closed with What is PR Today… and Where is it Going?, a candid look at the current state and future of communications. “Sometimes in PR, you have to say, ‘That’s not going to happen,’” said Gabrielle Gambrell of Hachette Book Group. Anthropologie’s Kate Haldy underscored values-driven storytelling: “Gen Z is shopping for values, purpose, and alignment… and holding brands accountable.” Josh Rosenberg of Day One Agency reflected on changing targeting strategies: “Culture is so niche now - it’s about connecting the brand truth to the fan truth.” Vanessa von Bismarck of BPCM offered a closing thought: “AI can make the grunt work easier, but we’re still in the business of human connection.” The 2025 Future Focus Conference offered a day of thought leadership, bold ideas, and meaningful connection - cementing its role as a must-attend event for marketers, communicators, and creatives shaping what’s next. The PR Net extends sincere thanks to the sponsors and event partners whose support made Future Focus possible. We are especially grateful to our presenting sponsors, Armanino and Suso Partner Club, for their generous contributions. Additional thanks go to our outstanding vendors and creative collaborators: AV by Total Entertainment, staging by 11th Street Workshop, stage furniture by CondeHouse and Rarify, photography and videography by Primal, and florals by FDK Florals. Notable brands and agencies in attendance included: L’Oréal, Dove, ULTA Beauty, Marriott International, IKEA, Hilton, Anthropologie, Rothy’s, Rimowa, Roger Dubuis, Blancpain, Sotheby’s, OpenAI, Substack, Impact.com, Fohr, Whalar, WeArisma, Edelman, 5WPR, BerlinRosen, BPCM, Day One Agency, Magrino, Prosek Partners, Derris, Hunter, LaForce, M Booth, The Brandman Agency, The Brand Guild, Zapwater Communications, Quinn PR, Ruder Finn, Rachel Harrison Communications, Resnicow and Associates, LDPR, Sharma Brands, Untitled Secret, INFRM, NeueHouse, J/PR, Preferred Travel Group, Two Trees Management, Bermuda Tourism Authority, The Ned. ABOUT THE PR NET: The PR Net is the premier global network for marketing and communications professionals. It is a modern take on the classic networking club and an "industry insider favorite” for executives looking for a central platform for industry intelligence and connections. Founded by industry veteran Lisa Smith in 2015, The PR Net consists of online content that reads like a magazine, member-only services, and highly sought-after digital and in-person member events. Contact Details The PR Net Sara Sturges ssturges@theprnet.com Company Website https://theprnet.com/

April 14, 2025 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Japanese Influencers Showcase the Richness of Peruvian Cuisine

Promperu

Peru made a vibrant and flavorful impression at Expo 2025 Osaka-Kansai with a gastronomic showcase highlighting the country’s rich biodiversity and culinary heritage. Japanese family-focused influencers enthusiastically shared their experience on social media, generating excitement and curiosity among their audiences. The influencers were treated to a menu of traditional Peruvian dishes such as ceviche and causa, which left a lasting impression. These are the same dishes that will be offered free of charge at the Peruvian Pavilion during Expo 2025 Osaka-Kansai. They were amazed by the explosion of flavors, textures, and colors in each dish—each crafted with native ingredients that tell the story of Peru’s diverse regions, from the Pacific coast and Andes mountains to the Amazon rainforest. Visitors appreciated the deep connection between Peruvian cuisine and its natural environment. Through videos, photos, and posts, the influencers spotlighted unique native ingredients such as ají amarillo (Peruvian yellow hot pepper), rocoto (red hot pepper), choclo (giant corn), and native potatoes. Their enthusiastic content sparked a wave of admiration and curiosity for the Peruvian Pavilion across Japan. Under the theme “Endless Possibilities”, the pavilion will showcase all of Peru’s charm—including its diverse cultural heritage, abundant natural beauty, world-renowned cuisine, and high-quality products. Designed to inspire and inform, the pavilion invites visitors to explore Peru’s history, creativity, and vision for the future: a world of endless possibilities waiting to be discovered. The official inauguration of the Peruvian Pavilion at Expo 2025 Osaka-Kansai will take place this Sunday, April 13, and will be attended by the Minister of Foreign Trade and Tourism, Desilú León Chempén, who will preside over the opening ceremony. Find out more about Peru's participation in Expo 2025 Osaka Kansai on social media: https://www.instagram.com/peru.expo2025/ https://x.com/peruatexpo https://www.tiktok.com/@peruatexpo https://www.youtube.com/@Peruatexpo2025 Peru Export and Tourism Promotion Board (PROMPERÚ). We are the government agency in charge of the development and implementation of global strategies to position Peru via the promotion of its image, touristic destinations, added value exports and investments. Contact Details José Carlos Collazos jcollazos@promperu.gob.pe Company Website http://www.promperu.gob.pe

April 11, 2025 06:37 PM Eastern Daylight Time

Image
Article thumbnail News Release

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

OSTX DAWN GSK ADCT

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031—a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology—using naturally occurring canine cancers as research models—are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that’s evolving faster than ever before. Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let's take a closer look at how some of the most innovative players in this space are tackling these pressing challenges. OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company’s lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein. Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients. This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease. The combination of these results marks a critical milestone in OS Therapies' development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026. The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects. As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans. Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term. The company’s growth isn’t limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology. As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer. Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer. OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption—more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone. In late 2024, OJEMDA also earned the “Exclusively Pediatric” designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One’s pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026. Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA. From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million—largely due to R&D and launch costs—the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts. Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer. GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK’s experimental antibody-drug conjugates (ADCs) that targets B7-H3—a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who’ve already gone through two lines of treatment. That’s a big deal in a space with no currently approved therapies for patients at that stage. Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK’s drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly. On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK’s pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year—including a relaunch of its blood cancer drug Blenrep—the company looks well-positioned to keep growing in high-need treatment areas. ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine). Recent clinical trial results further solidify the company’s growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company’s profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear. Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication. From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts. For investors, ADC Therapeutics presents a compelling opportunity, particularly as the company progresses through key trials and works towards expanding the indications for ZYNLONTA. Despite the competitive landscape, ADC Therapeutics has demonstrated its ability to deliver results that could appeal to both oncologists and patients, positioning the company for future growth. The promising clinical data, solid cash position, and ongoing commitment to advancing its ADC technology make ADC Therapeutics a stock worth keeping on the radar. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OSTX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 11, 2025 07:00 AM Eastern Daylight Time

Article thumbnail News Release

XLF Fund Opens Doors to U.S. Financial Sector

Select Sector SPDR

The Financials Select Sector SPDR Fund ( XLF ) stands as an option for investors seeking exposure to the dynamic U.S. financial sector. By incorporating a broad range of financial stocks from the S&P 500, XLF provides a streamlined entry point to one of the most pivotal segments of the economy. A Balanced Fund XLF employs a modified market capitalization-weighted index strategy, offering investors a balanced approach to financial sector investment. This methodology focuses on well-established, large-cap companies while also capturing sub-sectors such as banking, insurance, credit services, and capital markets. Notable Holdings* Include: Berkshire Hathaway B – 13.98% JP Morgan Chase – 9.82% Visa A – 8.65% Mastercard A – 6.39% Bank of America– 3.96% Wells Fargo – 3.38% Goldman Sachs – 2.44% Progressive – 2.37% S&P Global – 2.29% American Express– 2.14% This mix of holdings provides exposure to various segments of the financial sector. Accessibility for All Investors For investors aiming to enter the financial sector without the complexity of picking individual stocks, XLF presents an accessible and straightforward option. By pooling a collection of financial stocks, the fund eliminates the heavy lifting involved in individual stock selection, making it a practical choice for both seasoned and new investors. A Seamless Gateway to the Financial Sector XLF is engineered to enable investors to take advantage of the financial sector’s critical role in the economy. With its portfolio focused on the financial components of the S&P 500, it provides exposure to various aspects of the financial sector. For more information about the Financial Select Sector SPDR Fund (XLF) and how it may serve your investment needs, please visit our website @ sectorspdrs.com. XLF offers an efficient and accessible pathway into the U.S. financial sector. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 3/31/25 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL008350 EXP 6/30/25 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

April 11, 2025 05:00 AM Eastern Daylight Time

Article thumbnail News Release

Troy Davidson Joins Ballast Rock Private Wealth as a Wealth Advisor

Ballast Rock

Ballast Rock Private Wealth (“BRPW”), the independently run registered investment advisor that provides holistic financial advice to accredited high-net-worth individuals, today announced that Troy Davidson has joined the firm as a Wealth Advisor, with a focus on serving high- and ultra-high-net-worth clients. At BRPW, Davidson will work closely with clients to provide for their holistic financial needs, including complex estate planning, tax minimization, and wealth management as viewed through a multi-generational prism. “Troy is a highly experienced financial advisor who will play an important role in helping us build the ultra-wealth side of our business,” said BRPW CEO Andrew Mescon. “We feel fortunate to bring on Troy, who has nearly two decades of experience and a long career ahead of him. Additionally, Troy is a strong leader and mentor who can help advise the larger team on how to cater to clients with a diverse array of financial needs and pain points.” Most recently, Davidson was a Vice President Financial Consultant at Charles Schwab, where he managed more than 300 household relationships valued at more than $1.6 billion, including $480 million in assets under management. In that role, he earned a Key Contributor Award—for being in the top 20% in the company—five consecutive years, and was a Chairman’s Circle recipient, for being in the top 10% of the company, in 2021. His previous experience includes having served as a Vice President Financial Consultant at Fidelity Investments and as a Wealth Management Advisor at Merrill Lynch. “It’s exciting to join a team with so much growth potential,” Davidson said. “I’m impressed by everyone at Ballast Rock Private Wealth, and I look forward to being a part of this stellar community and helping to build a bright future for both the company and our clients.” Davidson is a Chartered Wealth Strategist and a Certified Private Wealth Advisor. He holds an MBA and bachelor’s degree from San Diego State University. About Ballast Rock Private Wealth Ballast Rock Private Wealth is an independent Registered Investment Advisor that provides holistic financial advice to accredited high-net-worth individuals. The firm, formed in 2022 by investment management firm Ballast Rock, focuses on offering objective, unbiased guidance with an enhanced focus on alternative investments. Contact Details For Ballast Rock Private Wealth press@ballastrock.com Company Website https://www.ballastrockpw.com/

April 10, 2025 10:30 AM Eastern Daylight Time

Article thumbnail News Release

Dr Hala Medical Aesthetics Introduces New Holistic Approach to Enhance Wellness and Beauty

Rev Up Marketers

Dr Hala Medical Aesthetics is the first clinic to adopt a holistic wellness philosophy that synchronizes advanced medical aesthetic treatments with holistic practices in a refined beauty paradigm centered on internal and external well-being. This is an example of how the industry is redefining aesthetics where clients want more than superficial treatments. They want total revitalization. The philosophy of the clinic is that true beauty comes from a healthy balance of internal and external care. Dr Hala Medical Aesthetics uses non-invasive procedures such as Botox, microneedling, chemical peels, and dermal fillers to help clients feel and look better. Medical aesthetic techniques the clinic specializes in are tailored to fine lines, acne, wrinkles, and other imperfections and use the latest technologies. These treatments also have two things in common; they are non-invasive and do not require any healing time. Precision is required. This approach is unique because it encourages optimal health and skin through lifestyle changes and nutrition. Incorporating stress management into aesthetic care is also important for this clinic's approach. Lowering cortisol concentrations through meditation and acupuncture alleviates inflammation and improves inflammatory skin conditions. Additionally, hydration, dietary changes, and lifestyle modifications are suggested to improve skin texture, promote collagen production, and maximize the benefits of PRP and Microneedling treatments. Dr Hala Medical Aesthetics is the first in this field to implement such a two-dimensional model of caring for one’s self. It enables people to practice self-care that is radiant and balanced and does so in a sustainable way. The clinic aims to change the perception of aesthetic procedures as purely cosmetic by incorporating internal health with external physical health. About the Company One of the foremost clinics in London, Dr Hala Medical Aesthetics, integrates cutting-edge medical aesthetics with holistic wellness solutions. The clinic maintains a focus on safety, technology, and natural beauty. It offers clients customized solutions that address their aesthetic and health needs. For further media inquiries feel free to contact the Dr Hala Medical Aesthetics Team through the official website. Contact Details Dr Hala Medical Aesthetics Dr Hala Mahfoud info@drhala.co.uk Company Website https://www.drhala.co.uk

April 10, 2025 09:20 AM Eastern Daylight Time

Article thumbnail News Release

Cure Hydration Expands Nationwide Retail Presence with Launch in Whole Foods Market

Cure Hydration

Cure Hydration, the leading premium, plant-based hydration brand known for its science-backed, electrolyte-rich formula, today announced its launch into Whole Foods Market locations nationwide. Cure Hydration’s Kids line has begun rolling out in 500+ Whole Foods stores, with five additional products from Cure Hydration’s core lineup rolling out over the next month. This expansion signifies a major milestone in the brand’s mission to offer better hydration solutions for health-conscious consumers across the U.S. Cure Hydration’s unique formula, based on the World Health Organization’s Oral Rehydration Solution (ORS) standards, delivers optimal replenishment with 4x the electrolytes of leading sports drinks, without any added sugars or artificial sweeteners. Made with simple, plant-based ingredients like coconut water and pink Himalayan salt, Cure delivers effective hydration powered by nature - ensuring efficient replenishment for active families and individuals. A nutritious and great-tasting alternative to sugary beverages, Cure’s products are vegan, gluten-free, and non-GMO, with natural ingredients like fruit juice powders and monk fruit. Whether you're hitting the gym, going on a hike, or simply looking to stay hydrated, Cure is made for everyone – and now even more accessible, with Cure’s launch in Whole Foods Market. "We’re beyond excited to launch Cure Hydration in Whole Foods Market, a destination for consumers who prioritize high-quality, better-for-you products," said Lauren Picasso, CEO and Founder of Cure Hydration. "As a leader in the natural foods industry, Whole Foods has set the standard for clean, high-quality ingredients, making this partnership a perfect match. At Cure, we believe hydration should be both effective and healthy, which is why we use a science backed formula without the added sugar or artificial junk. Being on Whole Foods shelves is a huge step forward in our mission to make hydration accessible to everyone, helping people feel their best every day.” In addition to a commitment to premium, science-backed formulas, Cure also focuses on delivering great taste and community impact initiatives (a mission that echoes Whole Foods Markets’ commitments). Cure’s products come in stick pack packaging that uses 95% less plastic than the average 12-oz bottled beverage. Through a partnership with rePurpose Global, Cure’s packaging is certified plastic-neutral and the company offsets plastic waste to ensure that hydration on-the-go doesn’t come at the expense of the environment. Cure also donates servings of its products to those in need, and supports local organizations like New York Common Pantry, City Harvest, and GrowNYC. Andy Jackson, Principal Category Merchant at Whole Foods Market added, “At Whole Foods Market, our mission is to nourish people and the planet by offering the highest quality products made with ingredients customers can trust. Cure Hydration’s commitment to plant-based hydration aligns perfectly with our values, providing a science-backed, effective way for shoppers to stay hydrated - without added sugars or artificial ingredients. We’re thrilled to offer Cure’s solutions to our shoppers nationwide, giving our customers a convenient and effective way to stay hydrated with ingredients they can trust.” With the initial launch of Cure Kids and additional core products rolling out later this spring, Cure Hydration is well-positioned to become a go-to solution for those seeking effective, clean hydration options. Cure Kids will be available in-stores in three kid-friendly flavors: Fruit Punch, Pink Lemonade, and Mixed Berry. Starting this spring, the brand’s core product line will offer a refreshing range of flavors, including Berry Pomegranate, Lemonade, Tropical Punch, Watermelon, and Strawberry Kiwi, catering to a variety of tastes and preferences. Whether at home or on-the-go, Cure is committed to providing consumers with the best hydration solutions to keep their bodies performing at their best. About Cure Hydration Cure Hydration is a premium hydration brand offering a refreshing, science-backed electrolyte mix made from plant-based, non-GMO ingredients. Created to provide rapid hydration and enhance overall health, Cure is formulated with the perfect balance of sodium, potassium, and glucose, ensuring optimal rehydration. Cure products are free from added sugar, artificial sweeteners, and synthetic colors and dyes, making them a healthier choice for people of all ages. Cure is committed to sustainability, maintaining certified plastic neutral packaging, donating servings of Cure to communities in need, and offers carbon emissions offsets to customers purchasing via its website. For more information on Cure Hydration and to find a store near you, visit curehydration.com. Contact Details Powers PR Alex Turk +1 516-306-2373 alext@powers-pr.com

April 10, 2025 09:17 AM Eastern Daylight Time

Image
Article thumbnail News Release

Switched On London Highlights the Value of Professional Electricians in Home Electrical Work

Rev Up Marketers

Switched on London stresses the importance of hiring an electrician to perform any electrical work in a residential setting. Safety, efficiency, and long-term savings are the main reasons why they recommend hiring a professional electrician over DIY. Many homeowners see DIY electrical work as a great way to save some money and gain hands-on experience. Switched On London says that it also requires specialized equipment. Professional electricians are trained to work with these systems in an effective and safe manner. They reduce the risk of electrocution or fire and ensure all work is compliant. The company values experience and expertise. A professional electrician can quickly diagnose and solve problems because they have years of experience and training. Many people cannot learn their trades on the job. According to Switched on London, although DIY might appear cheaper initially, it can result in hidden costs and more expensive repairs. Hiring a professional can help homeowners save money because they don't have to spend time or money buying expensive tools, nor do they need to learn how to troubleshoot unfamiliar systems. The firm claims that the long-term benefits, along with peace of mind are more important. In its latest communication, Switched on London stresses that hiring an electrician for your home is not only a convenience but a wise investment in terms of safety and durability. You can be confident that the work will meet industry standards and that you'll receive support if there are any problems. Switched On London encourages homeowners to make informed choices about their electrical projects. Before deciding whether to continue, they should weigh the risks and the complexity of the project. About the Company As a leading provider of electrical services in London, Switched on London is dedicated to providing reliable, safe, and code-compliant solutions for homes. Its reputation is based on its professionalism and transparency. For any additional questions, please contact the Switched On London media team through their website. Contact Details Switched On London Charlotte Goodwin-Bolda info@switchedon.london Company Website https://switchedon.london/

April 10, 2025 09:12 AM Eastern Daylight Time

1 ... 34567 ... 3862